丹红注射液辅助治疗对糖尿病肾病患者血小板CD62p、血小板激活复合物-1表达的影响

发布时间：2018-03-12 11:51

本文选题：丹红注射液　切入点：糖尿病肾病　出处：《中国老年学杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的观察丹红注射液辅助治疗对糖尿病肾病(DN)患者血小板活化依赖性颗粒表面膜蛋白(CD62p)、血小板激活复合物(PAC)-1表达的影响。方法 95例DN患者随机分为对照组与治疗组,治疗组在常规疗法的基础上静注丹红注射液(20 ml/次),采用流式细胞术检测治疗前后CD62p、PAC-1的表达。结果治疗前两组DN患者的血小板CD62p、PAC-1无显著差异;对照组常规治疗后血小板CD62p、PAC-1无明显变化;治疗组联合丹红注射液治疗显著降低了血小板CD62p、PAC-1阳性表达率;且治疗组治疗后的血小板CD62p、PAC-1显著低于对照组治疗后。结论丹红注射液辅助治疗可明显抑制DN患者血小板活化,这对于降低血栓形成是有利的。
[Abstract]:Objective to observe the effect of Danhong injection on the expression of platelet activation dependent granule membrane protein (CD62pN) and platelet-activated complex (PAC- 1) in patients with diabetic nephropathy (DN). Methods 95 patients with DN were randomly divided into two groups: control group and treatment group. In the treatment group, the expression of CD62ptPAC-1 was detected by flow cytometry on the basis of routine therapy. Results there was no significant difference in platelet CD62pPAC-1 between the two groups before and after treatment. In the control group, there was no significant change in platelet CD62pnPAC-1 after routine treatment, and the positive expression rate of platelet CD62pnPAC-1 was significantly decreased in the treatment group combined with Danhong injection. The platelet CD62pnPAC-1 after treatment in the treatment group was significantly lower than that in the control group. Conclusion the adjuvant treatment with Danhong injection can significantly inhibit platelet activation in patients with DN, which is beneficial to reduce thrombus formation.
【作者单位】：河北北方学院附属第一医院;天津医科大学代谢病医院;秦皇岛卫生学院;
【分类号】：R587.2;R692.9

【参考文献】